Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
Thomas D Meyer, Maya Ibrahim, Lauren N Vale, Jair C Soares
Journal of Affective Disorders March 15, 2025 DOI: 10.1016/j.jad.2024.12.044 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Randomized Peer reviewed |
|---|---|
| Population | Individuals with bipolar disorder who used psychedelics recreationally |
| Duration | Three-month follow-up |
| Keywords | Psychedelic drugs Behavioral health care Depression research Bipolar disorder Mental health treatment Mood disorders Time-line follow back Psychedelics hallucinogens Entheogens Bipolar affective disorder Psychological intervention |
| Citations | 6 |
| Key findings | Recreational psychedelic use in individuals with bipolar disorder was associated with reduced depressive symptoms and cannabis use, and more symptom-free days, without significant increases in manic, psychotic, or anxiety symptoms. |
Abstract
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD. Using the Timeline Followback (TLFB) method, we assessed mood symptoms, substance use, and other mental health-related variables in the month before and three months following participants' most recent psychedelic experience. Results showed a significant reduction in depressive symptoms and cannabis use, an increase in the number of days without mental health symptoms, and an increase in the number of days with hallucinogen use. Importantly, no significant changes in (hypo)manic, psychotic, or anxiety symptoms were observed. These findings suggest that psychedelics may hold potential as a safe and effective treatment for BD, though further research, including randomized controlled trials, is needed.
Citations in the library
Cited by 6
- Contemplating versus having used psychedelics in bipolar disorder - What makes the difference? Journal of Affective Disorders February 1, 2026
- Psilocybin use in bipolar disorder: A comprehensive review Journal of Affective Disorders October 31, 2025
- Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study. BMJ Open July 13, 2026
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
- Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. Molecular Psychiatry May 29, 2026
and 1 more in the library
Cites 14
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up Journal of Psychopharmacology February 1, 2022
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology March 18, 2016
and 9 more in the library